{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:51:04Z","timestamp":1791481864221,"version":"4.3.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer therapy-related cardiovascular toxicity (CTR-CVT) is a leading non-cancer cause of morbidity and mortality. The 2022 ESC Guidelines define a multidisciplinary pathway in which baseline cardiovascular risk assessment is led by the treating oncology or haematology team, with cardiological involvement guided by the resulting risk; how this is put into practice in hospitals is poorly characterised. Previous surveys have described the treating specialties; we examined the receiving cardiologists and internists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cross-sectional online survey of physicians in cardiology, internal medicine, gynaecology and oncology at 1,435 German hospital departments (February\u2013October 2025). This pre-specified analysis addressed cardiological involvement in the pathway and in risk stratification, left-ventricular ejection fraction (LVEF)-decline thresholds, strain use and biomarker testing in a standardised high-risk scenario (a patient with pre-existing heart failure receiving anthracycline chemotherapy). Findings are self-reported; comparisons exploratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred twenty physicians responded (44 cardiologists, 28 oncologists, 27 gynaecologists, 21 internists; 73.3% academic or university hospitals). Risk stratification showed the lowest cardiological involvement (42.9%, 15\/35); 51.0% (26\/51) of cardiologists and internists performed it themselves or within a team, and 19.6% (10\/51) regarded it as the treating oncologist\u2019s task. LVEF-decline thresholds were asked in two non-equivalent versions and are reported separately. Any LVEF decline was regarded as cardiotoxicity by 38.2% (13\/34) of cardiologists and 61.5% (8\/13) of internists, and by 26.7% (4\/15) of gynaecologists and 39.1% (9\/23) of oncologists; a decline exceeding 10% points by 55.9% and 23.1%, respectively. Routine strain use was reported by 76.5% (26\/34) of cardiologists and 36.4% (4\/11) of internists. Twelve-month biomarker testing in this scenario was infrequent even in cardiology (20.6%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among these predominantly academic physicians, risk stratification had the least clearly assigned ownership, the LVEF decline regarded as relevant varied widely within each version, routine strain use differed between cardiology and internal medicine, and late post-treatment biomarker testing was infrequent even in cardiology. These hypothesis-generating findings identify targets\u2014assigned responsibility for risk stratification, explicit LVEF thresholds, implementation of routine strain imaging and structured post-treatment surveillance\u2014whose effect on CTR-CVT outcomes requires prospective testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40959-026-00588-7","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:57:12Z","timestamp":1791352632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardio-oncology from the consulting side: diagnostic thresholds, surveillance and treatment responsibility among cardiologists and internists in a German multicentre survey"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7691-6458","authenticated-orcid":false,"given":"Sebastian","family":"Poley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2604-7962","authenticated-orcid":false,"given":"Lorena","family":"Payo-Anez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix M.","family":"Heidrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4053-4202","authenticated-orcid":false,"given":"Marian","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-4098","authenticated-orcid":false,"given":"Tina","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-2670","authenticated-orcid":false,"given":"Lorenz","family":"Harst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8599-4790","authenticated-orcid":false,"given":"Silvio","family":"Quick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"588_CR1","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37:2768\u2013801.","journal-title":"Eur Heart J"},{"key":"588_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43:280\u201399.","journal-title":"Eur Heart J"},{"key":"588_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31:171\u201390.","journal-title":"Ann Oncol"},{"key":"588_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the ESC in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22:1945\u201360.","journal-title":"Eur J Heart Fail"},{"key":"588_CR5","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361.","journal-title":"Eur Heart J"},{"key":"588_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Negishi T, Somerset E, et al. Strain-guided management of potentially cardiotoxic cancer therapy (SUCCOUR). J Am Coll Cardiol. 2021;77:392\u2013401.","journal-title":"J Am Coll Cardiol"},{"key":"588_CR7","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981\u20138.","journal-title":"Circulation"},{"key":"588_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","volume":"6","author":"M Camilli","year":"2024","unstructured":"Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM. Anthracycline cardiotoxicity in adult cancer patients: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2024;6:655\u201377.","journal-title":"JACC CardioOncol"},{"key":"588_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.1631","volume":"22","author":"L Michel","year":"2020","unstructured":"Michel L, Mincu RI, Mahabadi AA, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020;22:350\u201361.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"588_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/eurheartj\/ehz935","volume":"41","author":"R Asteggiano","year":"2020","unstructured":"Asteggiano R, Aboyans V, Lee G, Salinger S, Richter D. Cardiology care delivered to cancer patients. Eur Heart J. 2020;41(2):205\u20136. Survey report: European Society of Cardiology, Council of Cardio-Oncology and Council for Cardiology Practice. Cardiology care delivered to cancer patients: a survey of the Council of Cardio-Oncology and of the Council for Cardiology Practice of the European Society of Cardiology. Sophia Antipolis: European Society of Cardiology; 2019.","journal-title":"Eur Heart J"},{"key":"588_CR11","doi-asserted-by":"publisher","first-page":"e02","DOI":"10.15420\/ecr.2023.49","volume":"20","author":"S Quick","year":"2025","unstructured":"Quick S, Payo-Anez L, Marx C, de Almeida C, et al. Interdisciplinary management of cardiotoxicity in outpatient settings: a survey on practices, perceptions and potential for improvement. Eur Cardiol. 2025;20:e02.","journal-title":"Eur Cardiol"},{"key":"588_CR12","doi-asserted-by":"publisher","unstructured":"Poley S, Payo-Anez L, Heidrich FM, et al. Cardio-oncology care in German hospitals: a multicentre inpatient survey of practices, perceptions and guideline gaps. Clin Res Cardiol. 2026. https:\/\/doi.org\/10.1007\/s00392-026-02985-5.","DOI":"10.1007\/s00392-026-02985-5"},{"key":"588_CR13","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","volume":"22","author":"R Pudil","year":"2020","unstructured":"Pudil R, Mueller C, \u010celutkien\u0117 J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the ESC. Eur J Heart Fail. 2020;22:1966\u201383.","journal-title":"Eur J Heart Fail"},{"key":"588_CR14","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37:1671\u201380.","journal-title":"Eur Heart J"},{"key":"588_CR15","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jama.2023.11887","volume":"330","author":"TG Neilan","year":"2023","unstructured":"Neilan TG, Quinaglia T, Onoue T, et al. Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial. JAMA. 2023;330:528\u201336.","journal-title":"JAMA"},{"key":"588_CR16","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","volume":"40","author":"P Lancellotti","year":"2019","unstructured":"Lancellotti P, Suter TM, L\u00f3pez-Fern\u00e1ndez T, et al. Cardio-oncology services: rationale, organization, and implementation. Eur Heart J. 2019;40:1756\u201363.","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"588_CR17","doi-asserted-by":"publisher","first-page":"e2024S114","DOI":"10.1590\/1806-9282.2024s114","volume":"70","author":"JPP Dutra","year":"2024","unstructured":"Dutra JPP, Macedo AVS, Peixoto TFLF, et al. Cardiology and oncology: a meeting of giants. Rev Assoc Med Bras (1992). 2024;70(Suppl 1):e2024S114.","journal-title":"Rev Assoc Med Bras (1992)"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00588-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00588-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00588-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:03:30Z","timestamp":1791479010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00588-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["588"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00588-7","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"31 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Owing to the anonymous nature of the survey and the absence of identifiable patient data, formal ethics-committee approval was not required, as confirmed in writing by the data-protection officer of the TUD Dresden University of Technology. Informed consent for participation was obtained from all participants via a mandatory consent box on the first page of the online questionnaire before any items were answered.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; the manuscript contains no identifiable individual data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"123"}}